Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
FierceBiotech10d
UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
Targeted Oncology7d
Low-Dose Pembrolizumab Shows Promise vs Standard Dose in Stage IV NSCLC
A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...
Medpage Today on MSN7d
Coffee and Heart, Metabolic Risks; What Drives Doctors Away; Ozempic for $100?
Habitual moderate coffee consumption-- 200-300 mg of caffeine/day -- was tied to a lower risk of cardiometabolic ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Targeted Oncology7d
Upfront Belrestotug and Dostarlimab Betters Responses in PD-L1–High NSCLC
The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...